Earlier this month, Revance Therapeutics Inc RVNC named Mark Foley as its new CEO.
The addition of a commercial-focused CEO, with experience in unlocking shareholder value in aesthetics, is a “major positive,” according to Wells Fargo.
Wells Fargo’s Jacob Hughes upgraded Revance Therapeutics from Market Perform to Outperform raising the price target from $12.50 to $20.
Mark Foley’s strong track record of commercial success in aesthetics is particularly important, as Revance Therapeutics is transitioning from a development stage to commercialization, Hughes said in the upgrade note.
He added that the new CEO will also focus on reducing the company’s operating expenses to curb the rate of cash burn.
Hughes mentioned that Revance Therapeutics had several catalysts over the next six to twelve months, the most notable of which is a biologics license application (BLA) submission for DaxibotulinumtoxinA (DAXI) for treatment of glabellar lines by the end of November.
“Revance growth potential is significant in a multi-billion neurotoxins market, targeting both aesthetic and therapeutic indications,” the analyst wrote. He added that these markets were poised for continued expansion and that disruption from the merger between Allergan plc AGN and AbbVie Inc ABBV could create opportunities to take share.
Shares of Revance Therapeutics rose slightly to close trading at $15.42 on Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.